N-<<(chloromethyl)oxy>carbonyl>-L-proline methyl ester | 161395-43-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-<<(chloromethyl)oxy>carbonyl>-L-proline methyl ester
• 英文别名: (S)-N-[(chloromethyloxy)carbonyl]proline methyl ester；N-([chloromethyl]oxy)carbonyl-L-proline methyl ester；1-O-(chloromethyl) 2-O-methyl (2S)-pyrrolidine-1,2-dicarboxylate
• CAS: 161395-43-3
• 化学式: C₈H₁₂ClNO₄
• 分子量: 221.641
• InChiKey: MVZCWQPTFCUNHT-LURJTMIESA-N

物化性质

• 沸点：
  284.4±35.0 °C(Predicted)
• 密度：
  1.332±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  55.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-<<(chloromethyl)oxy>carbonyl>-L-proline methyl ester 在 sodium iodide 作用下， 以 丙酮 为溶剂， 反应 1.0h， 生成 (S)-N-[(iodomethyloxy)carbonyl]proline methyl ester
  参考文献：
  名称：

  Acyloxymethyl as a drug protecting group. Part 6

  摘要：

  Tertiary N-acyloxymethyl- and N-[(aminocarbonyloxy)methyl]sulfonamides were synthesised and evaluated as novel classes of potential prodrugs of agents containing a secondary sulfonamide group. The chemical and plasma hydrolyses of the title compounds were studied by HPLC, Tertiary N-acyloxymethylsulfonamides are slowly and quantitatively hydrolysed to the parent sulfonamide ill pH 7.4 phosphate buffer, with half-lives ranging from 20 h, for 7d, to 30 days, for 7g. Quantitative formation of the parent sulfonamide also occurs in human plasma, the half-lives being within 0.2-2.0 min for some substrates. The rapid rate of hydrolysis can be ascribed to plasma cholinesterase, as indicated by the complete inhibition observed at. [eserine] = 0.10 mM. These results suggest that tertiary N-acyloxymethylsulfonamides are potentially useful prodrugs for agents containing a secondary sulfonamide group, especially with pK(a) < 8, combining a high stability in aqueous media with a high rate of plasma activation. In contrast, N-[(aminocarbonyloxy)methyl]sulfonamides 7h-j do not liberate the parent sulfonamide either in aqueous buffers or in human plasma and thus appear to be unsuitable for development as sulfonamide prodrugs. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(00)00015-8
• 作为产物：
  描述：

  L-脯氨酸甲酯 、 氯甲酸氯甲酯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 N-<<(chloromethyl)oxy>carbonyl>-L-proline methyl ester
  参考文献：
  名称：

  [EN] COMPOUNDS AND THERAPEUTIC USES THEREOF
  [FR] COMPOSÉS ET LEURS UTILISATIONS THÉRAPEUTIQUES

  摘要：

  这项发明涉及化合物、药物组合物和方法，用于治疗癌症、全身性或慢性炎症、类风湿性关节炎、糖尿病、肥胖症、T细胞介导的自身免疫疾病、缺血以及与这些疾病和疾病相关并发症。

  公开号：

  WO2014004884A1

文献信息

• Synthesis, Stability and In Vitro Dermal Evaluation of Aminocarbonyloxymethyl Esters as Prodrugs of Carboxylic Acid Agents
  作者：Eduarda Mendes、Tânia Furtado、João Neres、Jim Iley、Tomi Jarvinen、Jarkko Rautio、Rui Moreira

  DOI：10.1016/s0968-0896(01)00336-4

  日期：2002.3

  Aminocarbonyloxymethyl esters based on (S)-amino acid carriers were synthesised and evaluated as potential prodrugs of carboxylic acid agents. In addition, the compounds were evaluated as topical prodrugs with the aim of improving the dermal delivery of two non-steroidal anti-inflammatory agents: naproxen and flufenamic acid. The lipophilicities of these compounds were determined and their hydrolyses

  合成了基于（S）-氨基酸载体的氨基羰基氧基甲基酯，并将其评估为潜在的羧酸试剂。此外，该化合物被评估为局部用药，目的是改善两种非甾体类抗炎药：萘普生和氟苯那酸的透皮给药。测定这些化合物的亲脂性，并检查它们在水溶液和人血浆中的水解。含有仲氨基甲酸酯基团的化合物通过两种不同的途径在pH 7.4下水解：（i）对酯羰基碳的直接亲核攻击导致母体羧酸的释放和（ii）涉及O-> N酰基的分子内重排迁移，导致形成相应的酰胺。重排途径高度依赖于羧酸和氨基酸取代基的大小，当氨基酸为缬氨酸或亮氨酸时被消除。相反，化合物仅在血浆中通过酯水解分解，大多数化合物定量释放母体羧酸，半衰期少​​于5分钟。在体外研究了选定的前药在切除后的人体皮肤中的渗透性。评估的所有前药均显示出比相应的母体羧酸更低的通量。对于化合物观察到的较差的皮肤渗透性最可能是由于其低的水溶性和高的分配系数。最多可定量释放母体羧酸，半衰期少​​于5分钟。
• PRODRUG COMPOUNDS USEFUL AS CANNABINOID LIGANDS
  申请人：Nelson Derek W.

  公开号：US20110144165A1

  公开（公告）日：2011-06-16

  The present invention provides for compounds of formula (I) wherein A 2 , L 2 , R 1g , R 2A , R 3A , R 4A , R 1a , R 1b , q1, and z are as defined in the specification, are prodrugs of CB 2 receptors ligands and as such are useful in the prevention and treatment of various diseases and conditions including, but not limited to, pain.

  当前发明提供了公式（I）的化合物 其中A 2 ，L 2 ，R 1g ，R 2A ，R 3A ，R 4A ，R 1a ，R 1b ，q1和z如说明书所定义，是CB 2 受体配体的前药，因此可用于预防和治疗包括但不限于疼痛的各种疾病和状况。
• N-(Acyloxyalkyl)pyridinium Salts as Soluble Prodrugs of a Potent Platelet Activating Factor Antagonist
  作者：Steven K. Davidsen、James B. Summers、Daniel H. Albert、James H. Holms、H. Robin Heyman、Terrance J. Magoc、Richard G. Conway、David A. Rhein、George W. Carter

  DOI：10.1021/jm00052a001

  日期：1994.12

  Pyrrolothiazole 4 is a potent antagonist of platelet activating factor-mediated effects in a variety of in vitro and in vivo assays. Despite its positive activity in models of inflammation and septic shock, 4 lacks the aqueous solubility necessary for intravenous administration. This deficit was overcome by conversion of 4 to water-soluble pyridinium prodrugs. A two-step procedure was used to prepare a series of N-(acyloxyalkyl)pyridinium salts, all of which exhibited aqueous solubility of greater than 20 mg/mL. The rate of conversion of these prodrugs to 4 was faster in human plasma than in pH 7 aqueous buffer. This rate difference was shown to be due to serum enzymes since the conversion in plasma was significantly slower in the presence of a serine esterase inhibitor. A strong correlation between prodrug structure and buffer/plasma half-life was established. The N-(acetyloxymethyl)pyridinium prodrug 11 (ABT-299) is currently undergoing clinical evaluation for the treatment of sepsis.
• A Highly Efficient Azide-Based Protecting Group for Amines and Alcohols
  作者：Srinivasu Pothukanuri、Nicolas Winssinger

  DOI：10.1021/ol0707160

  日期：2007.5.1

  The azide-based carbamate or carbonate protecting group (Azoc) shown above can be removed in less than 2 min under neutral conditions using trimethyl or tributyl phosphine as well as polymer-bound triphenyl phosphine. It was shown to be orthogonal to Fmoc and Mtt for peptide synthesis and to afford beta-glycoside with a 2-aminoglucosyl donor by virtue of the neighboring group participation.
• US8536336B2
  申请人：——

  公开号：US8536336B2

  公开（公告）日：2013-09-17